Publications

Journal Article
Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.
Ppublish 4192 citations
Electronic publication date
December 20, 2011

View on Pubmed.gov 21944779 | View on doi.org 10.1016/j.neuro...

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Search for publications in this journal Neuron - 72(2):257-68

ITALSGEN Consortium

Abstract

The chromosome 9p21 amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) locus contains one of the last major unidentified autosomal-dominant genes underlying these common neurodegenerative diseases. We have previously shown that a founder haplotype, covering the MOBKL2b, IFNK, and C9ORF72 genes, is present in the majority of cases linked to this region. Here we show that there is a large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 on the affected haplotype. This repeat expansion segregates perfectly with disease in the Finnish population, underlying 46.0% of familial ALS and 21.1% of sporadic ALS in that population. Taken together with the D90A SOD1 mutation, 87% of familial ALS in Finland is now explained by a simple monogenic cause. The repeat expansion is also present in one-third of familial ALS cases of outbred European descent, making it the most common genetic cause of these fatal neurodegenerative diseases identified to date.

References

Bioinformatics. 2009 Jul 15;25(14):1754-60

J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):196-203

J Neurochem. 2011 Oct;119(2):275-82

N Engl J Med. 2001 May 31;344(22):1688-700

Cited by 4192 citations (total)

Journal Article Research Support, Non-U.S. Gov't Review

Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies.

Electronic publication date November 11, 2011

Search for publications in this journal Int J Mol Sci

Akemi Ido [...] Makoto Urushitani et al.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive muscle wasting and weakness with no effective cure....

Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.

Electronic publication date February 13, 2015

Search for publications in this journal PLoS One

Luc Dupuis [...] Albert C Ludolph et al.

BACKGROUND

Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS).

METHODS/PRINCIPAL FINDINGS

We...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Copyright

Copyright © 2011 Elsevier Inc. All rights reserved.